Rheumatoid Arthritis Posts on Medivizor
Navigation Menu

Rheumatoid Arthritis Posts on Medivizor

Switching to an etanercept biosimilar – an investigation of the safety and efficacy profile

Posted by on Nov 10, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated if switching from etanercept (Enbrel) to a biosimilar of etanercept (SDZ-ETN) is safe and effective in patients with rheumatoid arthritis (RA). They found that switching to SDZ-ETN from reference etanercept was safe and effective.  Some background Rheumatoid arthritis (RA) is a long-term...

Read More

An update on the long-term safety and effectiveness of etanercept in juvenile idiopathic arthritis

Posted by on Oct 20, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the long-term safety and effectiveness of etanercept (Enbrel) in juvenile idiopathic arthritis (JIA).  They found that etanercept is well tolerated and effective on the long-term in patients with JIA.  Some background Juvenile idiopathic arthritis (JIA) is an inflammatory condition...

Read More

Golimumab in rheumatoid arthritis – investigating the safety and efficacy of intravenous administration

Posted by on Oct 20, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated golimumab (Simponi; GLM) in patients with rheumatoid arthritis (RA) in patients over 65 compared to those under 65.  They found that intravenous (IV) GLM was effective and well tolerated in these patients. Some background Rheumatoid arthritis (RA) is caused by chronic inflammation in the joints. RA...

Read More

Is there a greater risk of serious infection with tumor necrosis factor inhibitors for rheumatoid arthritis?

Posted by on Sep 27, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the risk of serious infections with tumor necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA). They found no difference in serious infection risk with TNFi treatment compared to triple therapy. Some background Rheumatoid arthritis (RA) is a chronic disease. It is caused by excessive...

Read More

Is upadacitinib more effective than adalimumab in patients with rheumatoid arthritis treated with methotrexate?

Posted by on Sep 20, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated upadacitinib (Rinvoq) versus adalimumab (Humira) as add-on to methotrexate in patients with rheumatoid arthritis (RA). They found that upadacitinib was more effective in improving RA symptoms compared to adalimumab. Some background Rheumatoid arthritis (RA) is an auto-immune...

Read More

Upadacitinib improves clinical outcomes of patients with rheumatoid arthritis

Posted by on Sep 10, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the safety and effectiveness of upadacitinib (Rinvoq) in patients with rheumatoid arthritis (RA) who progressed after methotrexate (Otrexup). Researchers suggested that upadacitinib improved clinical and functional outcomes in these patients. Some background RA is an autoimmune disorder which occurs when the...

Read More

How effective is filgotinib in the treatment of unresponsive rheumatoid arthritis?

Posted by on Aug 28, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the effectiveness of filgotinib (FGB) in patients with unresponsive rheumatoid arthritis (RA). They found that FGB improves RA management at 12 weeks.  Some background Rheumatoid arthritis (RA) is a chronic condition. Inflammation leads to painful swelling in the joints. RA is treated with...

Read More

Leflunomide – a review of its use in the treatment of juvenile idiopathic arthritis

Posted by on Aug 21, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the use of leflunomide (Arava) in juvenile idiopathic arthritis (JIA).   They found that this medication may be useful in managing JIA in patients resistant or intolerant to methotrexate.  Some background Juvenile idiopathic arthritis (JIA) is caused by inflammation in the joints. JIA is...

Read More

Remission with etanercept – what degree of remission predicts long-term success?

Posted by on Aug 14, 2019 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated if initial remission can predict long-term remission (LTR) after etanercept (Enbrel) treatment.  They found that LTR is more likely if strict disease control is achieved before etanercept withdrawal Some background Rheumatoid arthritis (RA) is a long-term condition. Disease-modifying anti-rheumatic...

Read More